Clinical usefulness of cimetidine for the treatment of acute intermittent porphyria--a preliminary report.

Abstract	A 43-yr-old man with abdominal fullness was treated with oral cimetidine during remission of acute intermittent porphyria. Urinary prophobilinogen and porphyrins were not altered by the treatment, but urinary delta-aminolevulinic acid decreased, and abdominal fullness disappeared. Thus, cimetidine may control acute intermittent porphyria by inhibiting hepatic delta-aminolevulinic acid synthetase.
Authors	Y Horie, M Udagawa, C Hirayama
Journal	Clinica chimica acta; international journal of clinical chemistry (Clin Chim Acta) Vol. 167 Issue 3 Pg. 267-71 (Aug 31 1987) ISSN: 0009-8981 [Print] Netherlands
PMID	3621613 (Publication Type: Case Reports, Journal Article)
Chemical References	Cimetidine Aminolevulinic Acid 5-Aminolevulinate Synthetase
Topics	5-Aminolevulinate Synthetase (antagonists & inhibitors) Acute Disease Adult Aminolevulinic Acid (urine) Cimetidine (therapeutic use) Humans Liver Diseases (drug therapy, metabolism) Male Porphyrias (drug therapy, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!